Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1956592 | 1.00 | BCL2 (0.75) | BCL2 | |
| SCHEMBL1955921 | 1.00 | BCL2 (0.75) | BCL2 | |
| SCHEMBL19425001 | 0.95 | — | — | |
| SCHEMBL1955503 | 0.95 | BCL2 (0.79) | BCL2 | |
| SCHEMBL1956575 | 0.95 | — | — | |
| SCHEMBL19424823 | 0.95 | — | — | |
| SCHEMBL1956573 | 0.95 | — | — | |
| SCHEMBL1956578 | 0.95 | — | — | |
| SCHEMBL19424466 | 0.94 | BCL2 (0.80) | BCL2 | |
| SCHEMBL1955368 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200222413-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC. | 2020-07-16 | — | — | US | claimed |
| US-20180369250-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC. | 2018-12-27 | — | — | US | claimed |
| EP-3028702-B1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE IRELAND UNLIMITED CO (IE) | 2018-09-12 | — | — | EP | claimed |
| US-9872861-B2 | Methods of treatment using selective Bcl-2 inhibitors | ABBVIE INC. (US) | 2018-01-23 | — | — | US | claimed |
| US-20170232000-A9 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC. | 2017-08-17 | — | — | US | claimed |
| EP-2507229-B1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC (US) | 2016-10-05 | — | — | EP | claimed |
| US-20160235760-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC (US) | 2016-08-18 | — | — | US | claimed |
| EP-3028702-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | AbbVie Bahamas Limited (BS) | 2016-06-08 | — | — | EP | claimed |
| US-9073855-B2 | BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2015-07-07 | — | — | US | claimed |
| US-20150150870-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBVIE INC. | 2015-06-04 | — | — | US | claimed |
| US-9045420-B2 | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | ABBVIE INC. (US) | 2015-06-02 | — | — | US | claimed |
| US-20140107119-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC. (US) | 2014-04-17 | — | — | US | claimed |
| US-20130296295-A1 | BCL-2 SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBVIE INC (US) | 2013-11-07 | — | — | US | claimed |
| EP-2642999-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | AbbVie Inc. (US) | 2013-10-02 | — | — | EP | claimed |
| WO-2012071374-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-31 | — | — | WO | claimed |
| US-20120129853-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-24 | — | — | US | claimed |
| US-20100298321-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | claimed |
| US-20250302827-A1 | Uses of Bcl-2 Antagonists for Treating Cancer and Diagnostics Related Thereto | UNIV EMORY (US) | 2025-10-02 | — | — | US | disclosed |
| WO-2011068561-A1 | SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20100298321-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296295-A1 | BCL-2 SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | BCL2 1/4885 |
| US-20200222413-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | BCL2 1/4885 |
| US-20150150870-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | BCL2 1/4885 |
| US-20160235760-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | BCL2 1/4885 |
| US-20140107119-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | BCL2 1/4885 |
| US-20250302827-A1 | Uses of Bcl-2 Antagonists for Treating Cancer and Diagnostics Related Thereto | BCL2, BCL2L2, BCL2L1 | BCL2 1/4885 |
| US-20170232000-A9 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | BCL2 1/4885 |
| US-20120129853-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | BCL2 1/4885 |
| US-20100298321-A1 | BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | BCL2, BCL3, BCL2L1 | BCL2 1/4885 |
| US-20180369250-A1 | METHODS OF TREATMENT USING SELECTIVE BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | BCL2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.